4//SEC Filing
Van Strydonck, Gerald E. 4
Accession 0001062993-24-010183
CIK 0001205922other
Filed
May 13, 8:00 PM ET
Accepted
May 14, 4:33 PM ET
Size
20.2 KB
Accession
0001062993-24-010183
Insider Transaction Report
Form 4
VACCINEX, INC.VCNX
Van Strydonck, Gerald E.
Director
Transactions
- Award
Stock Option (Right to Buy)
2024-05-10+10,108→ 10,108 totalExercise: $5.75From: 2025-05-10→ Common Stock (10,108 underlying) - Award
Common Stock
2024-05-10$5.75/sh+543$3,122→ 543 total
Holdings
- 182
Stock Option (Right to Buy)
Exercise: $72.75Exp: 2029-12-28→ Common Stock (182 underlying) - 1,905
Stock Option (Right to Buy)
Exercise: $32.25From: 2022-05-11→ Common Stock (1,905 underlying) - 9,589
Stock Option (Right to Buy)
Exercise: $6.15From: 2024-05-11→ Common Stock (9,589 underlying) - 514
Stock Option (Right to Buy)
Exercise: $116.70From: 2020-05-15→ Common Stock (514 underlying) - 426
Stock Option (Right to Buy)
Exercise: $204.00Exp: 2027-09-15→ Common Stock (426 underlying) - 123
Stock Option (Right to Buy)
Exercise: $107.55Exp: 2029-09-27→ Common Stock (123 underlying) - 3,550
Stock Option (Right to Buy)
Exercise: $16.80From: 2023-05-12→ Common Stock (3,550 underlying) - 166
Stock Option (Right to Buy)
Exercise: $78.90Exp: 2029-03-30→ Common Stock (166 underlying) - 159
Stock Option (Right to Buy)
Exercise: $82.80Exp: 2029-06-29→ Common Stock (159 underlying) - 1,045
Stock Option (Right to Buy)
Exercise: $59.25From: 2021-05-14→ Common Stock (1,045 underlying)
Footnotes (8)
- [F1]Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these restricted shares in lieu of $3,125 for retainer and meeting fees during the first quarter of 2024.
- [F2]Exercisable in full as of the date of this report.
- [F3]This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first.
- [F4]This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first.
- [F5]This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first.
- [F6]This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first.
- [F7]This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first.
- [F8]This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first.
Issuer
VACCINEX, INC.
CIK 0001205922
Entity typeother
Related Parties
1- filerCIK 0001748247
Filing Metadata
- Form type
- 4
- Filed
- May 13, 8:00 PM ET
- Accepted
- May 14, 4:33 PM ET
- Size
- 20.2 KB